Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: HIV/AIDS

In brief

The purpose of this study is to determine whether multiple doses of Efavirenz has an effect on the QTc interval (corrected by Fridericia) in CYP2B6 \*1/\*6 and \*6/\*6 healthy subjects.

Key facts

Study ID
NCT02164812
Run by
Bristol-Myers Squibb
People needed
58
Starts
2014-07-01
Expected to finish
2015-08-01
Last updated by the study team
2015-09-07

Who can join

Age: 18 and older, up to 49. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.